Inflammation-mediated rheumatic diseases and atherosclerosis

Annals of the Rheumatic Diseases

Volumn 59, Issue 5, 2000, Pages 321-325

  Wasko, Mary Chester M ^a   Manzi, Susan ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; SALICYLIC ACID; TUMOR NECROSIS FACTOR ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; HUMAN; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CORONARY ARTERIOSCLEROSIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS;

EID: 0034107276     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.59.5.321     Document Type: Article

References (66)

1. 1 Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jr, Jansen McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
2. 2 Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-9.
3. 3 Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-5.
4. 4 Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:338-46.
5. 5 Monson RR, Hall AP. Mortality among arthritics. J Chronic Dis 1976;29:459-67.
6. 6 Mutru O, Laakso M, Isomäki H, Koota K. Cardiovascular mortality in patients with rheumatoid arthritis. Cardiology 1989;76:71-7.
7. 7 Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
8. 8 Kroot EJA, van Leeuwen MA, van Rijswijk HM, Prevoo MLL, van't Hof M, van de Putte LBA, et al. No increased mortality in patients with rheumatoid arthritis. Arthritis Rheum 1998;41:S344.
9. 9 Myllykangas-Luosujärvi R, Aho K, Kautiainen H, Isomäki H. Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol 1995;22: 1065-7.
10. 10 Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997;24:445-51.
11. 11 Gabriel S, Crowson C, O'Fallon WM. Heart disease in rheumatoid arthritis (RA). Arthritis Rheum 1998;9(suppl):S132.
12. 12 Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:51-60.
13. 13 Hochberg MC, Petri M. The association of corticosteroid (CS) therapy with coronary heart disease (CHD) in patients with systemic lupus erythematosus (SLE): a meta-analysis. Arthritis Rheum 1991;34:R24.
14. 14 Esdaile JM, Abrahamowicz M, Grodzicky T, Senecal JL, Panaritis T, Li Y, et al. Myocardial infarction and stroke in SLE: markedly increased incidence after controlling for risk factors. Arthritis Rheum 1998;41(suppl 9):A639.
15. 15 Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med 1975;58:243-64.
16. 16 Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-11.
17. 17 Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Increased 16 alpha-hydroxylation of estradiol in systemic lupus erythematosus. J Clin Endocrinol Metab 1981;53:174-8.
18. 18 Lahita RG. The connective tissue diseases and the overall influence of gender. Int J Fertil Menopausal Stud 1996;41:156-65.
19. 19 De la Torre B, Hedman M, Nilsson E, Olesen O, Thörner A. Relationship between blood and joint tissue DHEAS levels in rheumatoid arthritis and osteoarthritis. Clin Exp Rheumatol 1993;11:597-601.
20. 20 Hedman M, Nilsson E, De la Torre B. Low blood and synovial fluid levels of sulpho-conjugated steroids in rheumatoid arthritis. Clin Exp Rheumatol 1992;10:25-30.
21. 21 Arnalich F, Benito-Urbina S, Gonzalez-Gancedo P, Iglesias E, de Miguel E, Gijon-Banos J. Inadequate production of progesterone in women with systemic lupus erythematosus. Br J Rheumatol 1992;31:247-51.
22. 22 Lahita RG, Kunkel HG, Bradlow HL. Increased oxidation of testosterone in systemic lupus erythematosus. Arthritis Rheum 1983;26:1517-21.
23. 23 Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994;91:6369-73.
24. 24 Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995;332:286-91.
25. 25 Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-81.
26. 26 Morgan SL, Baggott JE, Lee JY, Alarcon GS. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998;25: 441-6.
27. 27 Haagsma CJ, Blom HJ, van Riel PLCM. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1999;58:79-84.
28. 28 Pettersson T, Friman C, Nilsson B, Norberg B. Hyperhomocysteinemia in rheumatoid arthritis. Arthritis Rheum 1995;38(suppl):S336.
29. 29 Roubenoff R, Dellaripa P, Nadeau MR, Abad LW, Muldoon BA, Selhub J, et al. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum 1997;40:718-22.
30. 30 Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996;348:1120-4.
31. 31 Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340: 115-26.
32. 32 Mutru O, Koota K, Isomäki H. Causes of death in autopsied RA patients. Scand J Rheumatol 1976;5:239-40.
33. 33 Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
34. 34 Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332: 635-41.
35. 35 Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987;258:1183-6.
36. 36 Lozada C, Levin RI, Huie M, Hirschhorn R, Naime D, Whitlow M, et al. Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1. Proc Natl Acad Sci USA 1995;92:8378-82.
37. 37 Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM, Jr, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997;96: 4219-25.
38. 38 Reiss AB, Malhotra S, Javitt NB, Grossi EA, Galloway AC, Montesinos MC, et al. Occupancy of C1q receptors on endothelial cells by immune complexes downregulates mRNA for sterol 27-hydroxylase, the major mediator of extra-hepatic cholesterol metabolism. Arthritis Rheum 1998;41(suppl 9):A281.
39. 39 Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996;97:2063-73.
40. 40 Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996;98:826-37.
41. 41 Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA 1995;92: 4342-6.
42. 42 Mach F, Schönbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998;394: 200-3.
43. 43 Pasceri V, Yeh TH. A tale of two diseases. Atherosclerosis and rheumatoid arthritis. Circulation 1999;100:2124-6.
44. 44 van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44.
45. 45 Firestein GS. Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest 1999;103:3-4.
46. 46 Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999;99:1726-32.
47. 47 Moreland LW, Heck J, Koopman WJ. Biologic agents for treating rheumatoid: concepts and progress. Arthritis Rheum 1997;40:397-409.
48. 48 Abbot SE, Kaul A, Stevens CR, Blake DR. Isolation and culture of synovial microvascular endothelial cells. Characterization and assessment of adhesion molecule expression. Arthritis Rheum 1992;35:401-6.
49. 19 Ishikawa H, Hirata S, Nishibayashi Y, Imura S, Kubo H, Ohno O. The role of adhesion molecules in synovial pannus formation in rheumatoid arthritis. Clin Orthop 1994;300:297-303.
50. 50 Torre Amione G, Bozkurt B, Deswal A, Mann DL. An overview of tumor necrosis factor alpha and the failing human heart. Curr Opin Cardiol 1999;14:206-10.
51. 51 Gharavi AE, Wilson WA. The syndrome of thrombosis, thrombocytopenia, and recurrent spontaneous abortions associated with antiphospholipid antibodies: Hughes syndrome. Lupus 1996;5:343-4.
52. 52 Vaarala O, Manttari M, Manninen V, Tenkanen L, Puurunen M, Aho K, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995;91:23-7.
53. 53 Wu R, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997;17:3159-63.
54. 54 Galtier-Dereure F, Biron C, Vies M, Bourgeois V, Schved JF, Bringer J. Vascular complications of diabetes mellitus: what role for phospholipid-binding antibodies? Lupus 1998;7:469-74.
55. 55 Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 1994;84:2854-67.
56. 56 Vaarala O, Puurunen M, Lukka M, Alfthan G, Leirisalo Repo M, Aho K, et al. Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidized low-density lipoprotein. Clin Exp Immunol 1996; 104:269-74.
57. 57 Hörkkö S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest 1996;98:815-25.
58. 58 Pruzanski W, Goulding NT, Flower RJ, Gladman DD, Urowitz MB, Goodman PJ, et al. Circulating group II phospholipase A2 activity and antilipocortin antibodies in systemic lupus erythematosus. Correlative study with disease activity. J Rheumatol 1994;21:252-7.
59. 59 Wu R, Huang YH, Elinder LS, Frostegård J. Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL. Arterioscler Thromb Vasc Biol 1998;18:626-30.
60. 60 Elinder LS, Dumitrescu A, Larsson P, Hedin U, Frostegård J, Claesson HE. Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler Thromb Vasc Biol 1997;17:2257-63.
61. 61 Wu R, Svenungsson E, Gunnarsson I, Andersson B, Lundberg I, Schäfer Elinder L, et al. Antibodies against lysophosphatidylcholine and oxidized LDL in patients with SLE. Lupus 1999;8:142-50.
62. 62 George J, Harats D, Gilburd B, Levy Y, Langevitz P, Shoenfeld Y. Atherosclerosis-related markers in systemic lupus erythematosus patients: The role of humoral immunity in enhanced atherogenesis. Lupus 1999;8: 220-6.
63. 63 Vaarala O, Alfthan G, Jauhiainen M, Leirisalo Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993;341: 923-5.
64. 64 Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997;107:569-73.
65. 65 Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994;344: 793-5.
66. 66 Puurunen M, Manttari M, Manninen V, Tenkanen L, Alfthan G, Ehnholm C, et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994;154:2605-9.